Silexion Therapeutics Corp 8-K Filings

Silexion Therapeutics Corp (SLXN) entered an inducement agreement under which holders agreed to exercise for cash 3,216,928 existing Series E warrants at a reduced $0.2603 per share, down from $0.65. The company expects approximately $0.84 million in gross proceeds before placement-agent fees and other offering expenses; closing is expected on or about September 29, 2026, subject to customary conditions. In connection with closing, it is reducing the exercise price to $0.2603 for all outstanding Series E warrants covering 3,846,161 shares.

The agreement provides for new warrants to purchase up to 6,433,856 shares—3,216,928 Series F and 3,216,928 Series G—at $0.2603 per share, subject to shareholder approval for exercise. Series F expire five years and Series G 24 months after the later of the authorized share increase date and the resale registration statement’s effective date. Silexion agreed to issue H.C. Wainwright & Co., LLC, its exclusive placement agent, warrants for up to 225,185 shares at $0.3254 per share and pay it a 7.0% cash fee and a 1.0% management fee on gross proceeds from the existing-warrant exercises. Net proceeds are expected to fund general corporate purposes.

Silexion Therapeutics Corp (SLXN) reported translational-study findings that SIL204 used naturally occurring serum lipoproteins to enter human KRAS-driven cancer cells and produce dose-dependent knockdown of mutant KRAS expression in a carrier-free assay. Depleting serum lipids significantly reduced gene-knockdown efficiency (P < 0.001), while adding exogenous human LDL did not change potency compared with complete serum.

The company described physiological lipid levels as sufficient for cellular uptake without artificial carriers, providing mechanistic support for its systemic subcutaneous delivery strategy. The findings are preclinical; in vivo pharmacokinetic, cellular-uptake kinetics and tissue-biodistribution evaluations are underway. SIL204 is in a Phase 2/3 clinical program for locally advanced pancreatic cancer, with site initiation and patient screening ongoing.

Silexion Therapeutics Corp (SLXN) received a Nasdaq notice on September 25, 2026, stating that its ordinary shares’ closing bid price was below the $1.00 per share minimum for 30 consecutive business days.

Nasdaq staff said a hearings panel would consider the deficiency when deciding whether to enable Silexion to remain listed on the Nasdaq Capital Market. The notice has no immediate effect on the ordinary shares’ listing: they continue to trade under SLXN, and the listed warrants continue to trade as usual under SLXNW.

Silexion Therapeutics Corp (SLXN) reported that neither the authorized share capital increase nor the reverse share split proposal was approved at its reconvened extraordinary general meeting on September 23, 2026. Holders of 2,208,353 ordinary shares, approximately 36.8% of issued and outstanding ordinary shares, were present in person or by proxy. Under the company’s articles, after half an hour without the standard quorum, the shareholders then present constituted a quorum.

The authorized share capital increase proposal received 536,203 votes in favor (24.6%) and 1,645,147 against (75.4%), with 27,003 abstentions. The reverse share split proposal received 571,411 votes in favor (25.9%) and 1,636,939 against (74.1%), with 3 abstentions. The percentages exclude abstentions.

Silexion Therapeutics Corp (SLXN) reports that on August 18, 2026 it received a Nasdaq delisting notice for failing to meet the Nasdaq Capital Market’s minimum $2,500,000 shareholders’ equity requirement under Listing Rule 5550(b)(1). The company’s Form 10-Q for June 30, 2026 reported shareholders’ equity of $44,000, and it does not meet alternative continued listing standards. Silexion, already under a Mandatory Hearings Panel Monitor, plans to appeal to a Nasdaq Hearings Panel by August 25, 2026 and present steps taken and planned to restore equity compliance. The company states there is no assurance the appeal will succeed or that additional time will be granted; if unsuccessful, trading in its ordinary shares and warrants would be suspended and a Form 25-NSE would remove them from Nasdaq.

Silexion Therapeutics Corp reported larger losses for the three and six months ended June 30, 2026 while advancing its lead RNAi candidate SIL204 into an active Phase 2/3 trial in locally advanced pancreatic cancer. Regulatory approvals in Israel and from Germany’s BfArM enabled trial initiation, with the first site activated at Tel Aviv Sourasky Medical Center in July 2026 and additional Israeli and German sites progressing toward activation. New preclinical immuno-oncology data showed statistically significant effects on MHC-I, FAS (CD95), and HLA-G across four KRAS mutations, supporting future combination with anti-PD-(L)1 checkpoint inhibitors.

R&D expenses rose to $2.2 million in the quarter and $3.6 million year-to-date, driving a net loss of $3.6 million for the quarter and $6.3 million for the six months. Cash and cash equivalents declined to $2.2 million and total assets to $4.2 million, while shareholders’ equity narrowed to $44 thousand. The company executed multiple capital-structure actions, including a 1-for-10 reverse split and a registered public offering with $2.5 million gross proceeds and approximately $2.1 million net proceeds, and highlighted substantial doubt about its ability to continue as a going concern in its financial statements.

Silexion Therapeutics Corp reported updated historical financials to reflect a previously approved 1-for-10 reverse share split, on top of earlier 1-for-9 and 1-for-15 splits. All shares, per‑share data, options and warrants for 2024–2025 and March 31, 2026 have been retroactively adjusted.

For 2025, Silexion, a clinical‑stage RNAi oncology company with no revenues, recorded a net loss of $11.9 million and negative operating cash flow of $10.8 million. Cash and cash equivalents were $6.0 million and total assets $7.2 million as of December 31, 2025, against an accumulated deficit of $55.2 million. Shareholders’ equity improved from a deficit of $4.0 million at year‑end 2024 to positive equity of $2.6 million, mainly through public offerings, warrant exercises and note conversions.

The independent auditor issued an unqualified opinion but highlighted substantial doubt about Silexion’s ability to continue as a going concern, citing recurring operating losses, negative operating cash flows and limited liquidity. Management discloses that existing cash is expected to fund operations for only several months from the financial statement issuance date and that additional financing will be required.

Silexion Therapeutics Corp completed a best-efforts public offering of equity and warrants. The company sold 2,028,619 ordinary shares, 1,817,542 pre-funded warrants and 3,846,161 Series E ordinary warrants at a combined price of $0.65 per share and accompanying warrant (and $0.6499 per pre-funded warrant and accompanying warrant), generating approximately $2.5 million in gross proceeds and about $2.1 million in net proceeds. The Series E warrants are immediately exercisable at $0.65 per share for five years; the pre-funded warrants are exercisable at $0.0001 per share until fully exercised.

The company also issued 269,231 placement agent warrants at an exercise price of $0.8125 and paid the placement agent an 8% combined cash and management fee plus expenses. In connection with the closing, Silexion converted $750,001 of its sponsor note into 1,153,848 ordinary shares at $0.65 per share, reducing the note balance to $206,462. After the offering, note conversion, ATM sales and pre-funded warrant exercises, Silexion preliminarily estimates shareholders’ equity at approximately $3.2 million, and plans to use the proceeds primarily to advance its SIL204 clinical trial and for general corporate purposes.

Silexion Therapeutics Corp furnished an updated corporate presentation outlining development plans for its lead siRNA oncology candidate SIL204, which targets KRAS-driven tumors such as locally advanced pancreatic cancer. The program’s Phase 2/3 clinical trial in locally advanced pancreatic cancer was initiated in July 2026 after regulatory approvals in Israel and Germany, using a dual intratumoral and subcutaneous dosing strategy.

The presentation highlights preclinical data showing broad KRAS silencing at sub-nanomolar concentrations, tumor growth inhibition in mouse models, and established safety margins of up to 11-fold over the clinical starting dose in GLP toxicology studies with no systemic organ toxicity. The Phase 2/3 design includes a small safety run-in (about 15–18 patients) followed by randomized segments enrolling approximately 166 and 222 patients. Early human data are expected in Q4 2026, with an IND submission planned for Q1 2027 to expand the program to the U.S. and additional EU countries.

Silexion Therapeutics Corp reported new preclinical data for SIL204, an RNAi therapy targeting KRAS-driven cancers. In human pancreatic and non-small cell lung cancer cell lines with KRAS G12D, G12V, and G12C mutations, SIL204 increased expression of the immune death receptor FAS and reduced expression of the immune checkpoint HLA-G, both in a statistically significant, dose-dependent manner.

Together with previously reported MHC-I upregulation in KRAS G12R-mutant pancreatic cells, the findings suggest a coordinated immune-sensitization profile across four KRAS mutations and three immune pathways: antigen presentation, apoptosis sensitivity, and checkpoint reduction. Silexion is advancing SIL204 into Phase 2/3 clinical evaluation, following initiation of its first clinical trial site at Tel Aviv Sourasky Medical Center in July 2026.

Silexion Therapeutics Corp reported changes to its Board and audit committee. Professor Amnon Peled notified the Board of his resignation from the Board and all committees, including the audit committee, effective August 1, 2026. His resignation was for personal reasons and did not result from any disagreement regarding the company’s operations, policies, or practices.

Immediately upon his resignation becoming effective, the Board appointed existing independent director Avner Lushi to the audit committee, filling the vacancy. The Board determined that Lushi meets the independence standards of Nasdaq Listing Rule 5605(c)(2)(A) and SEC Rule 10A-3(b)(1). With his appointment, the audit committee now consists of three independent members—Dror J. Abramov (chair and audit committee financial expert), Ruth Alon, and Lushi—restoring full compliance with Nasdaq’s audit committee composition requirements without using the cure period.

Silexion Therapeutics Corp, a Cayman Islands company with Ordinary Shares and warrants listed on The Nasdaq Stock Market, reported a change in its Board of Directors. On July 30, 2026, Professor Amnon Peled notified the Board of his resignation as a director.

His resignation is for personal reasons and will be effective as of August 1, 2026. The company reports that his decision did not arise from any disagreement with Silexion regarding its operations, policies, or practices.

Silexion Therapeutics Corp. announced the successful initiation of its Phase 2/3 clinical trial of SIL204, a small interfering RNA (siRNA) candidate, in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, formally activating the first clinical site and clearing it to begin patient screening, with first dosing anticipated afterward.

The trial evaluates SIL204 plus standard-of-care chemotherapy using a dual-route strategy that combines intratumoral delivery to overcome stromal barriers with systemic administration to address metastatic disease. It begins with an initial safety run-in of approximately 18 patients, then expands globally to a randomized cohort of approximately 166 patients. SIL204 is designed to silence a broad range of KRAS mutations, which occur in about 90% of pancreatic cancers, 45% of colorectal cancers, and 30–35% of lung adenocarcinomas, supporting potential use across multiple KRAS-driven tumors.

Silexion Therapeutics Corp reported that at its reconvened extraordinary general meeting on July 20, 2026, shareholders approved changes affecting warrants and share capital. The meeting initially lacked a standard quorum, but under the company’s articles, shareholders present after a half hour constituted a valid quorum.

Holders of 230,276 ordinary shares, representing 21.7% of issued and outstanding ordinary shares, were present in person or by proxy. A New Warrant Exercisability Proposal passed with 214,091 votes (93.3%) in favor and 15,293 against. An Authorized Share Capital Increase Proposal passed with 205,551 votes (89.8%) in favor and 23,382 against. The associated Memorandum Amendment, which increases authorized share capital, became effective when filed in the Cayman Islands on July 21, 2026.

Silexion Therapeutics Corp has implemented a 1-for-10 reverse share split of its ordinary shares to help maintain compliance with Nasdaq’s minimum bid price requirements. The split became effective after the close of business on May 28, 2026, with trading on a split-adjusted basis beginning May 29, 2026 under the existing symbol SLXN.

Following the reverse split, authorized share capital remains at $796,500, now divided into 5,900,000 ordinary shares with par value increasing from $0.0135 to $0.135 per share. As of April 7, 2026, issued shares were consolidated from 4,074,710 to 407,471. The company also adjusted its public and private warrants so each whole warrant now reflects the 1-for-10 ratio and carries an exercise price of $15,525.00 per ordinary share, with no fractional shares issued on exercise.

Silexion Therapeutics Corp is implementing a 1-for-10 reverse share split of its ordinary shares. The split becomes effective after market close on May 28, 2026, with shares trading on a reverse split-adjusted basis on the Nasdaq Capital Market from May 29, 2026 under the symbol SLXN.

Every ten ordinary shares will be automatically combined into one share, and the par value will increase from $0.0135 to $0.135 per share. No fractional shares will be issued; eligible DTC participants will have any fractional entitlements rounded up to the nearest whole share. The company states that the reverse split is intended, among other things, to help maintain compliance with Nasdaq’s minimum bid price requirement and support its strategic plans as it advances its RNAi candidate SIL204 toward a Phase 2/3 trial in locally advanced pancreatic cancer.

Silexion Therapeutics reported first quarter 2026 results and highlighted progress for its lead RNAi candidate SIL204 in locally advanced pancreatic cancer. The Israeli Ministry of Health approved initiation of a Phase 2/3 clinical trial, and a Clinical Trial Application was submitted in Germany under the EU Clinical Trials Regulation, keeping trial initiation on track for the second quarter of 2026.

For the three months ended March 31, 2026, Silexion recorded a net loss of $2.7 million compared with $1.7 million a year earlier, driven by higher research and development expense of $1.4 million and general and administrative expense of $1.4 million. Cash and cash equivalents declined to $2.4 million from $6.0 million as of December 31, 2025, while shareholders’ equity fell to $0.3 million from $2.6 million, and a related party promissory note of $1.6 million was reclassified into current liabilities. Management noted warrant exercise inducements, at-the-market usage and shareholder approval for a prospective reverse share split as steps to support both clinical development and continued Nasdaq listing.

Silexion Therapeutics Corp entered into an inducement agreement with holders of 1,995,092 existing warrants to exercise them for cash at a reduced price of $0.50 per share, in exchange for 3,990,184 new warrants at the same exercise price. The company expects about $1.0 million in gross proceeds before fees, which it plans to use for general corporate purposes. New Series C and Series D warrants become exercisable only after shareholder approval and effectiveness of a resale registration statement and include 4.99% or 9.99% ownership limits, cashless exercise mechanics and five-year or 24‑month terms.

Silexion Therapeutics reported early laboratory findings suggesting its lead RNAi candidate SIL204 may have an immune-modulating effect in KRAS-driven cancers. In a preclinical study using human pancreatic cancer cells with a KRAS G12R mutation, SIL204 treatment led to a statistically significant increase in MHC-I (HLA-ABC) expression, a key signal that helps cytotoxic T cells recognize tumor cells. The company notes this could support future evaluation of SIL204 in combination with anti-PD-1 immunotherapies such as pembrolizumab, although these results remain preliminary and preclinical. Silexion is advancing SIL204 towards clinical trials in Israel and the European Union for locally advanced pancreatic cancer.

Silexion Therapeutics Corp is advancing its lead RNAi cancer drug SIL204 by starting Good Manufacturing Practice (GMP) clinical batch manufacturing with Catalent at its Limoges, France facility. These clinical batches will be used as investigational medicinal product for the safety run-in segment of a planned Phase 2/3 trial in locally advanced pancreatic cancer.

The company also received approval from the Helsinki Ethics Committee of Tel Aviv Sourasky Medical Center for the planned Phase 2/3 study at this leading Israeli oncology site, following prior authorization from the Israeli Ministry of Health and a Clinical Trial Application submission in Germany. Together, the manufacturing progress and multi-country regulatory steps move SIL204 closer to first patient dosing in a Phase 2/3 trial combining SIL204 with standard chemotherapy and using a dual-route (intratumoral and systemic) administration strategy.

Silexion Therapeutics Corp held a reconvened extraordinary general meeting on May 5, 2026, where shareholders approved several capital structure changes. The key step was a Memorandum Amendment increasing authorized share capital from US$121,500, divided into 9,000,000 ordinary shares, to US$796,500, divided into 59,000,000 ordinary shares, each with a par value of US$0.0135. Shareholders also approved an evergreen increase and a reverse share split proposal. The meeting proceeded after 1,638,079 ordinary shares, representing about 40.2% of issued and outstanding shares, constituted a quorum under the company’s articles. Each proposal received around 61% of votes cast in favor, meeting the simple majority threshold.

Silexion Therapeutics Corp furnished an update that it has successfully submitted a Clinical Trial Application in Germany for a planned Phase 2/3 trial of its lead siRNA therapy, SIL204, in KRAS-driven locally advanced pancreatic cancer. Germany will act as the Reporting Member State for the European Union review under the CTIS system, following earlier approval from the Israeli Ministry of Health for the same Phase 2/3 trial. The company plans to start the global Phase 2/3 study in the second quarter of 2026, combining intratumoral and systemic administration of SIL204 with standard chemotherapy at leading oncology centers in Germany, other EU states and Israel.

Silexion Therapeutics Corp reported a boardroom change, noting that its Board of Directors removed Ilan Levin from his role as a director, effective immediately on March 25, 2026. The remaining board members acted unanimously by written determination under Article 28.7 of the company’s Amended and Restated Articles of Association.

Silexion Therapeutics Corp reports that the Israeli Ministry of Health has formally approved a Phase 2/3 clinical trial of its RNAi therapy SIL204 in locally advanced pancreatic cancer. SIL204 is designed to silence a broad range of KRAS mutations, which occur in over 90% of pancreatic cancers, and has shown significant anti-tumor activity in multiple preclinical models with supportive toxicology data. The company expects to begin the Phase 2/3 trial in the second quarter of 2026, subject to site activation and standard readiness steps, and plans additional regulatory filings in Germany by the end of the current quarter and across the European Union in early 2027.

Silexion Therapeutics Corp reconvened its extraordinary general meeting on March 23, 2026 after the prior session was adjourned for lack of quorum. Shareholders present represented approximately 36.6% of issued and outstanding ordinary shares, which became a valid quorum under the company’s articles after a half hour.

Shareholders voted on an Authorized Share Capital Increase Proposal and an Evergreen Increase Proposal. The authorized capital proposal received 461,249 votes (38.2%) in favor and 744,775 (61.8%) against, with 10,345 abstentions. The evergreen proposal received 486,671 votes (40.7%) in favor and 709,115 (59.3%) against, with 20,583 abstentions. Neither proposal achieved the required simple majority of votes cast by shareholders present, so both measures were rejected.

Silexion Therapeutics Corp furnished an investor presentation in connection with a non-deal roadshow. The company prepared a corporate presentation dated February 2026 for use in meetings with investors, and attached it as Exhibit 99.1. This material is provided under Regulation FD as a furnished, not filed, communication under securities laws.

Silexion Therapeutics Corp announced it has submitted a Phase 2/3 clinical trial application in Israel for SIL204 in locally advanced pancreatic cancer. This step indicates the company is preparing to test SIL204 in a more advanced clinical setting, combining elements of mid- and late-stage evaluation.

The update was shared through a press release furnished under a Regulation FD disclosure, meaning the company is providing the same information to all market participants at the same time.

Silexion Therapeutics Corp filed a current report to share news about its pancreatic cancer program. On December 2, 2025, the company issued a press release titled “Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer.” This indicates that a German health authority has responded favorably to the company’s proposed design for a Phase 2/3 study, an important planning step before running a larger, later-stage trial.

The company is furnishing this press release under a Regulation FD disclosure, meaning it is providing the information broadly to the market. The disclosure is explicitly described as “furnished” rather than “filed,” so it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings.

Silexion Therapeutics Corp (SLXN) announced that it has successfully completed toxicology studies for SIL204, its next-generation RNA silencing therapy. These studies are a key safety step that supports moving SIL204 into a planned Phase 2/3 clinical trial in pancreatic cancer, a disease with limited treatment options. The update was provided through a press release that is included as an exhibit to this report.

The company’s ordinary shares and related warrants continue to trade on The Nasdaq Stock Market under the symbols SLXN and SLXNW, respectively. The disclosure is furnished under Regulation FD, meaning it is intended to provide broad, simultaneous information to the market rather than to update the company’s formal financial statements.

Silexion Therapeutics Corp announced it issued a press release with financial results for the third quarter ended September 30, 2025, and furnished the release as Exhibit 99.1. The company states this information is furnished and not deemed “filed” under Section 18 of the Exchange Act, and it is incorporated by reference only if specifically referenced in future filings.

Silexion’s securities listed on Nasdaq include Ordinary Shares (par value $0.0135) under ticker SLXN and Warrants (exercise price $1,552.50) under ticker SLXNW.

Silexion Therapeutics Corp filed a current report to share new preclinical research results for its drug candidate SIL204. On September 30, 2025, the company issued a press release titled “Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer.”

The report states that new human cell line data confirm pan-KRAS activity for SIL204, with inhibition reported as high as 99.7%, and describes first evidence related to gastric cancer. The press release is furnished as Exhibit 99.1, and this information is provided under Regulation FD as “furnished,” not “filed,” which limits its use in certain legal contexts.

Silexion Therapeutics Corp entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC and filed the agreement as an exhibit. The filing shows the company executed an arrangement to sell shares into the open market over time through the placement agent, providing a flexible means to raise capital as needed. The document includes an executed signature block by the Chief Executive Officer, indicating the agreement is authorized by management.

Silexion Therapeutics Corp. received a Nasdaq Compliance Letter confirming it has met the Nasdaq Capital Market's shareholder equity requirement and minimum $1.00 bid price requirement. The company completed financings that increased pro forma shareholders' equity by $10.3 million to approximately $9.41 million as of September 15, 2025. After a 1-for-15 reverse share split effected July 29, 2025, the closing price of the ordinary shares has been above $1.00. Nasdaq will monitor the company via a mandatory panel monitor through September 23, 2026, and a future equity deficiency during that period could lead to a delist determination and a new hearing opportunity.

Silexion Therapeutics Corp filed a current report describing a new press release about its oncology candidate SIL204. On September 11, 2025, the company reported positive preclinical data showing SIL204’s reach and activity in major pancreatic cancer metastatic sites after systemic administration. The press release is included as Exhibit 99.1 and incorporated by reference for additional scientific details. The disclosure is furnished under Regulation FD, meaning it is intended to provide broad, non-selective access to this research update without being treated as filed financial information.

Silexion Therapeutics Corp filed a current report to share news from a recent press release. The company announced that it has selected a contract research organization to support its upcoming Phase 2/3 clinical trials for its candidate SIL 204, marking a step toward more advanced clinical development.

The press release, dated September 4, 2025, is included as Exhibit 99.1 and is furnished under Item 7.01, meaning it is provided for informational purposes and is not deemed filed under the Exchange Act or incorporated by reference into Securities Act filings.

Silexion Therapeutics Corp furnished an updated corporate presentation that it plans to present on September 10, 2025 at the H.C. Wainwright Global Investment Conference in New York. The presentation was posted on the company’s website on September 2, 2025 and attached as Exhibit 99.1.

The company clarifies that this information is provided under a disclosure item that treats the material as “furnished” rather than “filed”, meaning it is not subject to certain liability provisions and will only be incorporated into other securities documents if specifically referenced.

Silexion Therapeutics Corp has furnished updated audited financial statements covering the year ended December 31, 2024. The filing lists the updated audited statements as an exhibit along with Inline XBRL instance and taxonomy extension documents. Contact and registration identifiers are provided for the Cayman Islands‑incorporated registrant, and the filing names Ilan Hadar in a signature role. No revenue, expense, or balance sheet figures are included in the disclosed text.

Silexion Therapeutics reconvened a shareholder meeting on August 19, 2025 after an earlier adjournment for lack of quorum. At the reconvened meeting, holders of 1,459,924 ordinary shares (approximately 16.8% of issued and outstanding shares) were present in person or by proxy. Under the company’s Articles, after a half-hour lapse without a majority quorum, the shareholders present constituted a valid quorum to transact business.

The shareholders approved a proposal to increase the company’s authorized share capital from US$20,000 (divided into 1,481,482 ordinary shares) to US$121,500 (divided into 9,000,000 ordinary shares), with the par value remaining US$0.0135 per share. The filing lists vote totals as 699,871 (59.8%), 470,828 (40.2%), and 289,225, and states the proposal was approved by a simple majority of shareholders present. The amendment is attached as Exhibit 3.1.

Silexion Therapeutics Corp filed a current report to let investors know it has released its financial results for the second quarter ended June 30, 2025. On August 12, 2025, the company issued a press release with these quarterly results, which is attached as Exhibit 99.1.

The company is furnishing this press release under the rules of the Securities Exchange Act, meaning it is provided for informational purposes and is not treated as formally filed under certain liability provisions. Details of the actual second-quarter performance, including specific revenue or profit figures, are contained in the referenced press release rather than in this report.

Silexion Therapeutics (SLXN) filed an 8-K announcing a 1-for-15 reverse share split effective after the 28-Jul-25 close. Authorized capital stays US$20,000 but is now divided into 1,481,482 ordinary shares; par value rises to US$0.0135. All issued and outstanding shares are reduced proportionally and will begin trading on a split-adjusted basis under the same ticker at the 29-Jul-25 open. The new ordinary-share CUSIP is G1281K 130.

The company simultaneously delivered a Warrant Adjustment Notice. Each pre-split warrant is now exercisable for 1/15th of a share, and the exercise price is lifted 15× to US$1,552.50 per post-split share. Fractional entitlements will be rounded up at the broker (DTC participant) level. Warrant CUSIP (G1281K 114) and ticker (SLXNW) are unchanged.

The split was approved at the 14-Jul-25 AGM and effected through an amendment to the Amended & Restated Memorandum of Association, filed 28-Jul-25. Items 3.03 and 5.03 detail the warrant modifications and charter amendment, while Item 8.01 incorporates these events by reference.

On July 16 2025 Silexion Therapeutics Corp ("SLXN") filed an 8-K announcing a 1-for-15 reverse share split affecting all issued, outstanding and authorized ordinary shares. The split will be effected automatically after market close on 28 Jul 2025, and the shares will begin trading on a split-adjusted basis on Nasdaq at the open on 29 Jul 2025; the ticker remains "SLXN".

• Every 15 existing shares convert into 1 new share.
• Par value increases from $0.0009 to $0.0135 per share.
• No fractional shares will be issued; DTC positions will be rounded up to the nearest whole share.

The Board’s goal is to raise the per-share price to maintain compliance with Nasdaq Capital Market listing standards. Warrants ("SLXNW") are expected to be adjusted pursuant to their terms. Additional details are provided in the press release attached as Exhibit 99.1.

Silexion Therapeutics Corp (NASDAQ: SLXN) filed a Form 8-K on 9 July 2025 under Item 7.01 (Regulation FD). The sole purpose of the filing is to furnish — not file — a press release (Exhibit 99.1) titled “Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines.” No additional financial statements or transaction details are included, and the company explicitly states the information is not incorporated by reference into other Securities Act filings.

Key points

• The press release reports positive preclinical efficacy for SIL204 in human lung cancer cell lines.
• The disclosure is furnished under Regulation FD, ensuring simultaneous public access to the information.
• No revenue, cost, guidance, or clinical-stage data accompany the announcement.
• Exhibits attached: 99.1 (press release) and 104 (Inline XBRL cover data).

Investors receive confirmation of encouraging scientific data but must consult Exhibit 99.1 for experimental specifics, as the 8-K itself contains minimal detail.

Silexion Therapeutics Corp (NASDAQ: SLXN) announced that a Nasdaq hearings panel has granted the company continued listing status, but with conditions. Effective July 8, 2025, the company’s ordinary shares and warrants will move from the Nasdaq Global Market to the Nasdaq Capital Market, keeping their current tickers “SLXN” and “SLXNW.”

The panel’s decision hinges on Silexion’s ability to achieve and maintain at least $2.5 million in shareholders’ equity by September 19, 2025 and to demonstrate that level in an SEC filing that includes a balance sheet dated within 60 days of submission. Nasdaq will retain jurisdiction over the company’s listing status until November 18, 2025; any further rule breaches before that date must be accompanied by an additional compliance plan for panel review.

Silexion also disclosed a potential bid-price deficiency (closing price below $1.00 for 30 consecutive trading days). Management intends to remedy this by executing a 1-for-15 reverse share split shortly after its reconvened annual general meeting on July 14, 2025, pending shareholder approval, with the split expected to take effect on or about July 25, 2025.

Key investor takeaway: Listing is preserved, but the company must raise equity or otherwise strengthen its balance sheet, complete the reverse split, and avoid additional rule breaches. Failure to meet these milestones could trigger delisting despite the current reprieve.